Rick Linforth retweeted
Watch the full highlights here! youtu.be/3bpjt6Bx-rU
Rick Linforth retweeted
THE INSPECTOR WHO INSPECTED TOO HONESTLY
Dr Shyam Kumar @ukorthopod is an orthopaedic surgeon. A good one. Unblemished record. So the Care Quality Commission (@CareQualityComm) recruited him as a part-time inspector to help hold NHS hospitals to account.
He took the job seriously. Too seriously, it turns out.
Between 2015 and 2019 he raised concerns about botched hospital inspections, a bullying culture inside the CQC itself, and a surgeon at Morecambe Bay whose hip replacement on an elderly patient left her unable to walk.
He asked the CQC to review that surgeon's cases. He was told the trust did not want to do so for reputational reasons.
A Royal College of Surgeons review later found problems with 26 out of 46 of that surgeon's operations.
The CQC's response to Kumar? They called his concerns fanciful. They dug for dirt on him. Then they sacked him.
In September 2022 a Manchester Employment Tribunal ruled he had been unfairly dismissed.
The tribunal found his safety disclosures had directly influenced the decision to get rid of him. The judgment noted that CQC officials spent their energy gunning him down rather than focusing on patient safety.
He was awarded £23,000 for injury to feelings.
Not damages for a ruined career. Not accountability for the officials who ran the smear operation. Just £23,000 and a declaration.
The CQC issued a statement saying it had learnt from the case and improved its processes. A decade earlier it said exactly the same thing after the Mid Staffordshire Public Inquiry found it had victimised its own whistleblowers then too.
The system that was built to protect patients ran a seven-year campaign against the man raising the alarm.
Then it said sorry and carried on.
Source: @BBCNews, The Guardian, BMJ, Westminster Confidential (@davidhencke)
Rick Linforth retweeted
Physical activity reduces all-cause mortality in patients with cancer
According to this meta-analysis including 13 RCTs👇
Exercise reduces all-cause mortality in cancer patients by 26%.
Not with drugs—through exercise!
cancertreatmentreviews.com/a…
Did you join us for our Beyond the Scalpel: Planning the Next Chapter webinar? ABS Members can now catch up on demand on the ABS Information Hub. Thanks again to our fantastic speakers Rishi Parmeshwar and Katherine Rogers. Watch here: buff.ly/JpFAYoT
Rick Linforth retweeted
Pathologic response and prognosis in HER2 + and TNBC .
#oncology #medtwitter
Rick Linforth retweeted
📣 Now available as open access on @JCO_ASCO: our analysis on extended endocrine therapy (ET) in premenopausal pts with eBC after 5y of LHRHa.
ascopubs.org/doi/10.1200/JCO…
Which are the pros and cons of extended ET in this setting? 🤔
A thread 🧵1/
@IEOufficiale @DFCI_BreastOnc
Rick Linforth retweeted
We’re preparing for the largest #MiamiBreast yet. Make sure not to miss it. Free registration using TARANTINO as promo code here: registration.gotoper.com/mbc…. See you there! 🏝️
Rick Linforth retweeted
🔥 PALLAS at #SABCS25
Final nail for adjuvant palbociclib ⚰️
7 year follow up shows no iDFS, DRFS, or OS benefit with adjuvant palbociclib.
Post recurrence OS appears shorter, driven by less CDK4/6 reuse and more visceral relapse.
🧪 Bottom line - palbociclib has no role in the adjuvant setting.
🔥 PALLAS at #SABCS25 : Still no role for adjuvant Palbociclib
Even with 7 year follow up, PALLAS again shows no gain in iDFS, DRFS, or OS with adjuvant palbociclib.
📉 OS after distant recurrence
Shorter in the palbo arm: 22.6 mo vs 27.9 mo for ET alone (HR 1.21).
💡 Why?
Palbo patients were less likely to receive CDK4/6i at recurrence and had more visceral relapses, pushing outcomes down.
After adjusting for post relapse treatments, the OS gap disappears.
🧪 Key message
Adjuvant palbociclib does not improve long term outcomes.
Post recurrence CDK4/6 access strongly influences OS signals.
#OncoTwitter #MedTwitter #BreastCancer #SABCS25 @OncoAlert @myesmo @esmo_open @ASCO
Rick Linforth retweeted
Less is more in the axilla at #SABCS25 💡🫁
#AXSANA shows that in cN1 → ypN0 after NACT, SLNB or TAD matches ALND for 3 year axillary control at ~99 percent 🎯
More surgery did not improve control. Smart de escalation preserves outcomes and quality of life 🌿
#medtwitter #BreastCancer
@OncoAlert @SABCSSanAntonio
Less can be more in the axilla at #SABCS25 💡🫁
New #AXSANA data shows that for patients converting from cN1 to ypN0 after NACT, SLNB or TAD matches ALND for 3 year axillary control.
Almost zero difference in recurrence. Almost zero reason to overtreat.
➡️ 3 year axillary recurrence free survival
SLNB 99.8 percent
TAD 98.5 percent
ALND 99.2 percent
(All confidence intervals overlapping)
➡️ Key message
More surgery did not translate into more regional control.
Axillary management can be safely de escalated in ycN0 after NACT, provided standards are met.
💭 Why it matters?
Avoiding ALND means fewer complications, better QoL, and similar oncologic outcomes.
#OncoTwitter #MedTwitter #BreastCancer #SABCS25 @OncoAlert @myesmo @esmo_open @asco
Rick Linforth retweeted
Management of Cancer During Pregnancy: ASCO Guideline
It is a remarkably comprehensive guide that addresses every question thoroughly👇
ascopubs.org/doi/10.1200/JCO…
Rick Linforth retweeted
NCCN Breast Cancer v5.2025 — Key Updates 🔍🎗️
The latest NCCN update continues the shift toward safe de-escalation in localized #BreastCancer :
• Axilla
SLNB can replace ALND in select patients → less morbidity with no compromise in outcomes.
@OncoAlert
#bcsm
Rick Linforth retweeted
Age and mutation-specific breast cancer risk👇
From Dr. Shani Paluch-Shimon’s presentation at #ESMO25
Rick Linforth retweeted
NCCN Breast Cancer Guidelines 2025 (v5) #update focuses on localized therapy:
• Less extensive axillary surgery—SLN biopsy may replace ALND in select pts.
• Hypofractionated post-mastectomy RT safe with reconstruction.
• Partial breast irradiation recommended for low-risk pts ≥40.
#BreastCancer #NCCN @Larvol @OncLive @ONCOLife_HP @OncoAlert
Rick Linforth retweeted
Interpreting liver blood test results can be challenging. How should clinicians interpret abnormal test results?
New Education article offers guidance and a visual summary
#BMJInfographic
🔗 bit.ly/4hYP9mF
Rick Linforth retweeted
Just out! The 2025 St. Gallen International #BreastCancer Consensus — redefining individualized therapy for early breast cancer.
From risk-adapted treatment to patient preference–driven decisions.
#BreastCancer #StGallen2025 #Oncology #ESMO #CancerCare @Larvol @OncoAlert @ONCOLife_HP @myESMO
Rick Linforth retweeted
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
📌Chest-wall irradiation didn’t improve survival in intermediate-risk early breast cancer after mastectomy with modern systemic therapy.
nejm.org/doi/full/10.1056/NE…
Rick Linforth retweeted
“Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24) corresponding to 1 additional case per 7752 users.”
Both combined and progestin-only contraceptives are linked to increased breast cancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. ja.ma/47vFzD3
Rick Linforth retweeted
Overall Survival with Abemaciclib in Early Breast Cancer
annalsofoncology.org/article…
Presented at #ESMO25
The phase 3 monarchE 🦋trial shows that adding abemaciclib to adjuvant endocrine therapy significantly improves overall, invasive disease–free, and distant relapse–free survival in high-risk HR+/HER2− early #BreastCancer with durable benefits and no late safety concerns.
@delmastro_lucia @JavierCortesMD @hoperugo @ErikaHamilton9 @Prof_Nadia_H
Rick Linforth retweeted
Have you read the ABS Mastectomy Avoidance Toolkit? A practical aid to reducing unnecessary mastectomies and supporting MDT decision making. Access the toolkit here: buff.ly/dmf6xpg









































